HPMC/Carbopol based extended release gastroretentive dosage form of losartan potassium: Formulation and in vivo pharmacokinetic evaluation in rabbits

Wani, Taha Umair; Mir, Khalid Bashir; Fazli, Abdul Aala; Raza, Syed Naiem; Khan, Nisar Ahmad

doi:10.1016/j.jddst.2020.102006

Cited by 5 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Water was readily available at the time of study for rabbits, but they were not permitted to consume solid food. The X-ray pictures were taken after 4 h and 12 h to track the presence of optimized floating matrix tablets in the stomach ( Shin et al, 2019 ; Wani et al, 2020 ; Younis et al, 2020 ).…”

Section: Methodsmentioning

confidence: 99%

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

Patel

Shelke²,

Surti³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

The present research is focused on developing floating matrix tablets of mitiglinide to prolong its gastric residence time for better absorption. Gastroretentive tablets were prepared using a direct compression technique with hydroxypropyl methylcellulose K15M (HPMC K15M) and sodium alginate as matrix-forming polymers and sodium bicarbonate as the gas-forming agent. A 32 full factorial design was adopted to optimize the flotation and release profile of the drug. The concentration of HPMC K15M and sodium alginate were taken as the independent variables, and the floating lag time, time required for 50% drug release, and time required for 90% drug release were taken as dependent variables. The compatibility between drug and excipients was assessed by Fourier transform infrared (FTIR) spectroscopy. The prepared tablets were evaluated for different parameters such as hardness, friability, drug content, floating time, in vitro dissolution, and stability. Dissolution data were analyzed using various kinetic models to ascertain the mechanism of drug release. Finally, a radiographic study was conducted to estimate the retention time of the optimized floating matrix tablets of mitiglinide inside the body. The results revealed that all the physical properties of the developed formulations were within standard limits. The formulation M3, with the maximum amount of both independent variables, was considered to be the optimized formulation based on the desirability value. In addition, the optimized M3 formulation showed stability for over 6 months, as evidenced by insignificant changes in lag time, drug release pattern, and other physical properties. Furthermore, radiographic examination indicated that the tablets remained afloat in gastric fluid for up to 12 h in the rabbit’s stomach. In conclusion, the developed floating matrix tablet of mitiglinide could be regarded as a promising formulation that could release the drug in the stomach at a controlled rate and, hence, offer better management of type II diabetes.

show abstract

Section: Methodsmentioning

confidence: 99%

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

Patel

Shelke²,

Surti³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Due to the swelling ability of both polymers, their low bulk density, and the ability of carbopol to form an insoluble network structure, a stable buoyant gel was formed. DF remained buoyant in the dissolution medium for more than 12 h and provided a delayed release of API during this time; in vivo, the capsule and the resulting gel were retained in the stomach for more than 8 h [78]. Kumar et al, used a mixture of carbomer (Carbopol 934) and HPMC to obtain gas-forming floating tablets containing calcium disodium salt of ethylenediaminetetraacetic acid.…”

Section: Carbomersmentioning

confidence: 99%

Polymeric Excipients in the Technology of Floating Drug Delivery Systems

Blynskaya

Tishkov²,

Vinogradov³

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

The combination of targeted transport and improvement of the release profile of the active pharmaceutical ingredient (API) is a current trend in the development of oral medicinal products (MP). A well-known way to implement this concept is to obtain floating gastroretentive delivery systems that provide a long stay of the dosage form (DF) on the surface of the stomach contents. The nomenclature of excipients (Es) of a polymeric nature used in the technology of obtaining floating drug delivery systems (FDDS) is discussed. Based on the data presented in research papers, the most widely used groups of polymers, their properties, and their purpose in various technological approaches to achieving buoyancy have been determined. In addition, ways to modify the release of APIs in these systems and the Es used for this are described. The current trends in the use of polymers in the technology of floating dosage forms (FDF) and generalized conclusions about the prospects of this direction are outlined.

show abstract

“…Drug release studies of LERC were conducted using dialysis bag diffusion (Wani and Khan, 2019). [7] Dialysis bags were filled with LERC and placed in a beaker of pH 7.4 phosphate buffer, which was maintained at room temperature. For the duration of the experiment, the beaker and magnetic stirrer were kept at a constant 37 ± 1°C.…”

Section: In Vitro Release Profile Of a Lercmentioning

confidence: 99%

Formulation Development and Release Profile of Levomilnacipran Extended Release Capsules using Principles of Quality by Design

Singh¹,

Choudhary²,

Kharia³

2022

APJHS

View full text Add to dashboard Cite

The study’s goal was to use Quality By Design (QbD) principles to design an Extended Release dosage form of levomilnacipran and evaluate its in vitro release profile. Doses of levomilnacipran extended release capsules (LERC) ranging from 20 mg to 120 mg. QbD was employed in this work to design LERC capsule formulation and production, which ensures LERC safety and efficacy. To create the LERC, wurster coating was applied to non-pariel seeds, which were then filled with capsules. To provide prolonged absorption, a polymer derived from ethylcellulose was chosen. Extensive release capsules are made up of four main components: (1) Drug layering, (2) extended release coating, (3) lubricant application, and finally (4) capsule filling. Results revealed that there was no significant difference in release profile LERC in different doses; however, the highest release of drug was seen at 120 mg, that is, 93%. The present formulation may be used as an effective treatment therapy against major depressive disorder.

show abstract

HPMC/Carbopol based extended release gastroretentive dosage form of losartan potassium: Formulation and in vivo pharmacokinetic evaluation in rabbits

Cited by 5 publications

References 36 publications

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

Polymeric Excipients in the Technology of Floating Drug Delivery Systems

Formulation Development and Release Profile of Levomilnacipran Extended Release Capsules using Principles of Quality by Design

Contact Info

Product

Resources

About